About
- History
CUREXO Technology Corporation is a pioneer in medical robotics and world leader in image-directed, robotic products for orthopaedic applications. The Company’s ROBODOC® Surgical System allows surgeons to pre-operatively plan their surgery in a 3-D virtual space and then execute the surgery exactly as planned in the operating theatre.
An early prototype of the ROBODOC System was developed in 1986 when IBM's Thomas J. Watson Research Center and researchers at the University of California, Davis began collaborative development of an innovative system for Total Hip Arthroplasty (THA).
In 1992, the ROBODOC System made medical history as the first of its kind to be used on humans, assisting a surgeon in a THA procedure. This breakthrough opened the way to rapid development of 3-dimensional image directed, pre-operative planning, and computer guided robotic surgery.
That year the ROBODOC development team was awarded the prestigious Computerworld Smithsonian Award for Innovation in the Arts and Sciences for Medicine.
In 1994 commercialization of the ROBODOC System began in Europe. Since then the Company has developed methods for pinless registration, Total Hip Arthroplasty with cementless implant, Total Knee Arthroplasty, and Revision Total Hip Arthroplasty.
By mid-2007, a partnership with a subsidiary of CUREXO Inc. of Korea allowed the Company to complete their clinical studies at three major United States hospitals and proceed with the next level of technical development. As the Company transitioned, CUREXO Technology Corporation emerged to continue developing and marketing its products into new markets worldwide.
Today, the ROBODOC System has assisted surgeons in more than 24,000 joint replacement procedures around the world in Europe, Japan, Korea and India. Development of new applications such as Hip Resurfacing, Acetabular Cup, Long Bone Osteotomies, Uni-Condylar Knee, and Multi-Compartmental Knee are currently underway for the ROBODOC System. Additionally, an expert team of International surgeons is being formed to further expand the capabilities of the ROBODOC System into Spine and Cranial surgeries.
In August 2008, the ROBODOC® Surgical System received 510(k) clearance from the United States Food and Drug Administration (FDA) for Total Hip Arthroplasty procedures. This milestone marks the only active robotic system cleared by the U.S. FDA for orthopaedic surgery.
- Introduction
- Ramesh C. Trivedi, Ph.D.
- Leland Witherspoon
Throughout the years, our management team has been dedicated to the advancement of the ROBODOC System. They have weathered the cycles of technical development, funding and regulatory testing needed to bring such an innovative system to the global market.
Senior management provides a strong sense of continuity and an understanding of the opportunities along with expertise and experience to move the company forward from this point. They are committed to enhancing the capabilities of surgeons and improving the outcomes of the surgery for patients.
President and Chief Executive Officer
Dr. Trivedi joined Integrated Surgical Systems in November 1995, and in his current position has guided the company through its transition into the new division of Curexo, Inc. He has been a Director of the company since 1995 and Chairman of the Board since September 2006.
Prior to that time, Dr. Trivedi was a Principal of California Biomedical Consultants, an international consulting firm. He also served as the President and Chief Executive Officer of DigiRad Corporation, a medical imaging company.
Dr. Trivedi received a Ph.D. in Chemical Engineering from Lehigh University, and holds an MBA from Pepperdine University.
Chief Technical Officer and Vice President of Operations
Mr. Witherspoon joined Integrated Surgical Systems in April 1997 as Vice President of Research and Engineering. Since June 2005, Mr. Witherspoon has held his current position. He has shepherded the technical advancement of the ROBODOC system through the fast--paced developments in 3D imaging capabilities and the meticulous requirements of surgical robotics over the past 11 years.
Previously, Mr. Witherspoon was Director of Product Research and Development for Sorin Biomedical, Inc., a developer and manufacturer of cardiopulmonary and cardiovascular hardware and software products. He has also held positions in technology and management for Pfizer/Shiley, Xerox Medical Systems and IBM.
Mr. Witherspoon has served on the Board of Directors for IMMI, a developer of neurosurgical robotic systems, and on various steering committees in conjunction with the Engineering Research Center at John Hopkins.
He holds patents in myocardial infusion and control systems and various technological developments in image capture and processing equipment, as well as various robotic control systems.
Mr. Witherspoon completed his undergraduate work at Rensselaer Polytechnic Institute and various advance degree work at the University of Vermont in Burlington and the University of Texas in Austin.
Chief Financial Officer, Open